SynCrest Launches CRDMO Service for Peptide-based Therapeutics- Integrated support across the drug development value chain
with continuous flow synthesis May 8, 2023
Fujisawa, Japan – SynCrest Inc., a peptide and nucleotide CRDMO (Contract Research, Developmentand Manufacturing Organization) joint venture between Otsuka Chemical Co., Ltd. and Yokogawa
Electric Corporation*1, announces its services are now available for pharmaceutical companies andresearch institutions in Japan, Europe, North America, and South America. Using its advanced
continuous flow synthesis with in-line measurement*2, the company can produce activepharmaceutical ingredients (APIs), intermediates, and raw materials while addressing the specificchallenges at each stage of the drug development value chain.
SynCrest delivers a one-stop service for peptide-based therapeutics, from library synthesis and processdevelopment for drug discovery through to manufacturing of experimental medicine for clinicalstudies, support for new product releases, and on-demand commercial manufacturing. In particular,
with the recent diversification of needs related to peptide-based therapeutics, demand is increasing forspecial amidites, which are nucleic acids that have been modified into a non-natural form, andpeptides containing non-natural amino acids, and so the company has been developing technology tomeet these latest demands in drug discovery research. Regarding nucleic acids, SynCrest has been able
to lower costs and dramatically improve purity of the amidites that comprise the raw material. With
respect to peptide synthesis, the company has developed a new manufacturing method for special
amino acids that enables the delivery of more than 100 types of non-natural amino acids with highquality and short lead time. SynCrest is also actively engaged in research on fluorine-related
compounds and is able to introduce fluorine in peptide and nucleotide compounds.
SynCrest has developed an industry-leading continuous flow synthesis method with in-line
measurement that enables non-destructive, high-precision measurements in real time. This technology
connects reaction, separation, concentration, and crystallization phases into a continuous flow andintegrates in-line monitoring, allowing unique responses to issues and needs related to quality,
delivery, and cost in the value chain. From special raw materials to intermediates and middlemolecular APIs, the company can provide rapid, highly efficient, and high-quality manufacturing toaccelerate a wide range of exploratory and drug discovery research.
Manufacturing of the APIs, intermediates and raw materials is carried out at SynCrest’s Naruto Plant
in Tokushima, Japan. This is the first multi-purpose, multi-product plant in the country to utilize thecontinuous flow synthesis method while being GMP*3-compliant for highly potent substances (OEBCategory 4*4). It also has a non-GMP area, enabling a diverse and flexible production system andenvironment.
SynCrest’s President and Representative Director, Pengyu Xu, stated, “We are very pleased that wehave reached this milestone of officially starting sales operations. With flow synthesis technology,
sensing technology, and an advanced management system as our three key pillars, we will address thequality, delivery, and cost challenges that exist in the development and manufacturing of peptide andnucleotide therapeutics, and aim to become a flagship CRDMO in this field by delivering exceptional
value for our customers throughout the entire process, from basic research through to commercialproduction.”
SynCrest is attending at TIDES USA, the industry’s largest event for oligo and peptide therapeutics(May 8-10, San Diego).
*1 Otsuka Chemical and Yokogawa Electric to Launch SynCrest Inc., a Joint Venture Targeting the CRDMO
Business for Middle-molecular Drugs*2 A flow synthesis method that enables process continuity by using in-line measurement to rigorously control
multiple processes in production, from reaction to purification/extraction.
*3 Standards for manufacturing and quality control for the production of safe and effective pharmaceuticals andfoods. Each country has its own rules and guidelines.
*4 Operational Exposure Band. This is the permissible exposure amount control category for active pharmaceuticalingredients.

About SynCrest
SynCrest helps researchers and producers of middle-molecular drugs be more productive by providing
integrated services ranging from basic drug research through to process development and commercialmanufacturing. We respond to challenges and needs related to quality, delivery, and cost in themanufacturing value chain for middle-molecular drugs and other pharmaceutical compounds byproviding the desired quantity of products at the right time and with optimal quality.
For more information, visit http://syncrest.com/en/